Q-Line Biotech Limited

<table><tr><td>Total</td><td>1,41,75,000</td></tr></table>

viii. Right issue of 5,24,999 Equity Share having face value of Rs. 10/- each fully paid up as on September 27, 2025, details of which are given below:

<table><thead><tr><td>Sr. No.</td><td>Name of Allottees</td><td>Number of Shares Allotted</td></tr></thead><tbody><tr><td>1.</td><td>Rajesh Kumar Upadhyay</td><td>40,000</td></tr><tr><td>2.</td><td>Amit Saraswat</td><td>32,000</td></tr><tr><td>3.</td><td>Amit Kumar Jain</td><td>16,000</td></tr><tr><td>4.</td><td>Bhupendra Singh Chuphal</td><td>32,000</td></tr><tr><td>5.</td><td>Alok Kumar Agarwal</td><td>2,09,400</td></tr><tr><td>6.</td><td>Dinesh Kantilal Doshi</td><td>32,000</td></tr><tr><td>7.</td><td>Santosh Yadav</td><td>4,000</td></tr><tr><td>8.</td><td>Mayank Mehrotra</td><td>8,000</td></tr><tr><td>9.</td><td>Bishal Kumar</td><td>50,000</td></tr><tr><td>10.</td><td>Neeraj Yadav</td><td>12,500</td></tr><tr><td>11.</td><td>Sudha Prabhakar</td><td>15,000</td></tr><tr><td>12.</td><td>Anita Singhal</td><td>30,000</td></tr><tr><td>13.</td><td>Monika Raj</td><td>30,000</td></tr><tr><td>14.</td><td>Jitesh Jauhari</td><td>5,000</td></tr><tr><td>15.</td><td>Ankit Rathi</td><td>5,099</td></tr><tr><td>16.</td><td>Puneet Gupta</td><td>4,000</td></tr><tr><td colspan="2">Total</td><td>5,24,999</td></tr></tbody></table>

b) Preference Share Capital

As on the date of this Draft Red Herring Prospectus, our Company does not have any Preference Share Capital.

3. Except as disclosed below our Company has not issued any Equity Shares for consideration other than cash since its incorporation.

<table><thead><tr><td>Date of Allotment</td><td>Number of Equity Shares</td><td>Face Value (Rs.)</td><td>Issue Price (Rs.)</td><td>Reasons for Allotment</td><td>Benefits Accrued to our Company</td><td>Name of Allottee</td><td>No. of Shares Allotted</td></tr></thead><tbody><tr><td rowspan="4">March 30, 2016</td><td rowspan="4">10,00,000</td><td rowspan="4">10/-</td><td rowspan="4">-</td><td rowspan="4">Bonus Issue in the ratio of 2:1</td><td rowspan="4">*Capitalization of Reserves & Surplus</td><td>Saurabh Garg</td><td>9,75,000</td></tr><tr><td>Amita Garg</td><td>20,000</td></tr><tr><td>Pushplata Garg</td><td>5,000</td></tr><tr><td><strong>Total</strong></td><td><strong>10,00,000</strong></td></tr><tr><td rowspan="10">August 28, 2025</td><td rowspan="10">1,41,75,000</td><td rowspan="10">10/-</td><td rowspan="10">-</td><td rowspan="10">Bonus Issue in the ratio of 9:1</td><td rowspan="10">*Capitalization of Reserves & Surplus</td><td>Saurabh Garg</td><td>91,23,300</td></tr><tr><td>Amita Garg</td><td>35,43,732</td></tr><tr><td>Pushplata Garg</td><td>67,500</td></tr><tr><td>Ajay Kumar Mahanty</td><td>6,75,000</td></tr><tr><td>Ayush Garg</td><td>28,350</td></tr><tr><td>Abhay Agrawal</td><td>6,80,409</td></tr><tr><td>Amit Agarwal</td><td>28,359</td></tr><tr><td>Shubham Garg</td><td>28,350</td></tr><tr><td><strong>Total</strong></td><td><strong>1,41,75,000</strong></td></tr></tbody></table>

*Above allotment of shares has been made out of Reserve & Surplus available for distribution to shareholders and no part of revaluation reserve has been utilized for the purpose.

4. No Equity Shares have been allotted pursuant to any scheme approved under sections 230-234 of the Companies Act, 2013 or under the erstwhile corresponding provisions of the Companies Act, 1956.

5. Our Company has not issued any shares pursuant to an Employee Stock Option Scheme.

74